United Therapeutics Corporation and Corsair Pharma have  entered into an exclusive license agreement for Corsair’s portfolio of patents covering treprostinil prodrugs. 

Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair’s intellectual property for the development of treprostinil prodrug formulations. Corsair will continue development of transdermal treprostinil prodrug formulations for PAH. Corsair received upfront consideration, and is entitled to royalty payments based on the commercialization of treprostinil prodrug products by United Therapeutics that are covered by Corsair’s patents.

In addition, United Therapeutics made a minority equity investment in Corsair that includes an option to acquire the remaining outstanding shares of Corsair. 

David Collier, chief executive officer of Corsair Pharma and Velocity Pharmaceutical Development, said, “We are excited to be working with United Therapeutics to develop prodrugs of treprostinil. Both of our companies are committed to developing therapies that meaningfully improve the lives of patients suffering from PAH.” 

This collaboration is intended to support the success of United Therapeutics’ RemoPro product, which is designed to bring subcutaneous treprostinil therapy to PAH patients without the infusion site pain currently associated with subcutaneous treprostinil therapy.